Iovance BiotherapeuticsIOVA -0.94%44 Current Ratio is 3.60 as of Mar. 2026, which is 58% below its 10-year median of 8.55. GuruFocus rates IOVA with a GF Score™ of 44/100 and a GF Value™ of $18.83 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Iovance Biotherapeutics ranks worse than 52.58% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Iovance Biotherapeutics's current ratio for the quarter that ended in Mar. 2026 was 3.60.
Iovance Biotherapeutics has a current ratio of 3.60. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Iovance Biotherapeutics's Current Ratio or its related term are showing as below:
IOVA'
s Current Ratio Range Over the Past 10 Years
Min: 2.79 Med: 8.55 Max: 56.53
Current: 3.6
During the past 13 years, Iovance Biotherapeutics's highest Current Ratio was 56.53. The lowest was 2.79. And the median was 8.55.
IOVA's Current Ratio is ranked worse than 52.58% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs IOVA: 3.60
Iovance Biotherapeutics (NAS:IOVA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Iovance Biotherapeutics Current Ratio Related Terms
Iovance Biotherapeutics Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOVA vs HRMY, NRIX, ZYME: Current Ratio Comparison
For the Biotechnology subindustry, Iovance Biotherapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iovance Biotherapeutics (IOVA) has a Current Ratio of 3.60 as of Mar. 2026. This is 58% below median its historical median of 8.55. Over the past decade, Iovance Biotherapeutics' Current Ratio has ranged from 2.79 to 56.53. According to the industry distribution chart, Iovance Biotherapeutics ranks #745 out of 1417 companies in the Biotechnology industry, placing it in the top 52.6%.
Is Iovance Biotherapeutics' Current Ratio too high?
Iovance Biotherapeutics' current Current Ratio of 3.60 is 58% below median its 10-year median of 8.55. Over the past 10 years, this metric has ranged from a low of 2.79 to a high of 56.53. The Biotechnology industry median Current Ratio is 3.89. Iovance Biotherapeutics' value of 3.60 is 7.5% below this industry median. Based on the distribution chart, Iovance Biotherapeutics ranks #745 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Current Ratio compare to HRMY and NRIX?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #745 out of 1417 companies for Current Ratio. This places Iovance Biotherapeutics in the lower half of its industry. The industry median Current Ratio is 3.89. Iovance Biotherapeutics' value of 3.60 is 7.5% below this benchmark. Historically, Iovance Biotherapeutics' own Current Ratio has ranged from 2.79 to 56.53 over the past decade. While the company's 10-year median is 8.55 vs. the industry median of 3.89, Iovance Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iovance Biotherapeutics's current Current Ratio of 3.60 is 7.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iovance Biotherapeutics's current Current Ratio is 3.60, which is 58% below median its own 10-year median of 8.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Possible Value Trap. The stock's GF Value™ is $18.83, compared to a current price of $4.21 — trading 77.6% below its estimated fair value. The current Current Ratio is 3.60, which is 58% below median its 10-year median of 8.55 and 7.5% below the Biotechnology industry median of 3.89. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current Current Ratio is 3.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued.
The current stock price of $4.21 is trading 77.6% below its estimated GF Value™ of $18.83.
GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.
Key valuation signals for IOVA:
Current Ratio: 3.60 (58% below median its 10-year median of 8.55)
GF Value™: $18.83 vs. price of $4.21 (77.6% below fair value)
Industry Position: 7.5% below the Biotechnology median (#745 of 1417)
No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score
Get the complete analysis for IOVA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOVA has been successfully added to your 
